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Edited by Miguel De la RosaAbstract The catalytic subunit of cAMP-dependent protein ki-
nase (PKA) can easily be expressed in Escherichia coli and is
catalytically active. Four phosphorylation sites are known in
PKA (S10, S139, T197 and S338), and the isolated recombinant
protein is a mixture of diﬀerent phosphorylated forms. Obtaining
uniformly phosphorylated protein requires separation of the pro-
tein preparation leading to signiﬁcant loss in protein yield. It is
found that the mutant S10A/S139D/S338D has similar proper-
ties as the wild-type protein, whereas additional replacement of
T197 with either E or D reduces protein expression yield as well
as folding propensity of the protein. Due to its high sequence
homology to Akt/PKB, which cannot easily be expressed in E.
coli, PKA has been used as a surrogate kinase for drug design.
Several mutations within the ATP binding site have been de-
scribed to make PKA even more similar to Akt/PKB. Two pro-
teins with Akt/PKB-like mutations in the ATP binding site were
made (PKAB6 and PKAB8), and in addition S10, S139 and
S338 phosphorylation sites have been removed. These proteins
can be expressed in high yields but have reduced activity com-
pared to the wild-type. Proper folding of all proteins was ana-
lyzed by 2D 1H, 15N-TROSY NMR experiments.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Protein kinases are a major protein class that regulate a mul-
titude of cellular processes. This is achieved by catalyzing the
transfer of the c-phosphate from ATP to the target protein,
thereby changing its activity. Due to their indispensable func-
tion in cellular signaling, deregulation of certain protein ki-
nases result in disease. Inhibition of these deregulated
protein kinases by small molecule inhibitors is pharmaceuti-
cally relevant [1,2]. Successful examples of this strategy are
Gleevec (imatinib), which inhibits cAbl [3], or Iressa (geﬁtinib),
which targets the kinase domain of EGFR [4]. Akt/PKB is a
protein kinase that has been found frequently in a constitu-
tively active form in human cancers. The central role of Akt/*Corresponding authors. Fax: +49 69 798 29515.
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doi:10.1016/j.febslet.2005.06.015PKB is well validated [5,6]. Therefore, obtaining speciﬁc small
molecule inhibitors for Akt/PKB is highly desirable. A major
obstacle on this way is the production of large quantities of
pure and active Akt/PKB protein for structural studies, since
it cannot be expressed in Escherichia coli in a functional form.
Furthermore, Akt/PKB has to be phosphorylated on the acti-
vation loop as well as in a regulatory sequence, called the
hydrophobic motif [6]. Since both PKA and Akt/PKB belong
to the AGC-family of protein kinases and share high sequence
homology, PKA has been used as a surrogate kinase for Akt/
PKB. To make PKA more similar to Akt/PKB distinct muta-
tions within the ATP-binding region have successfully been
produced [7,8]. PKA has also been used as a surrogate for
Rho-kinase [9].
Nearly all protein kinases are regulated by phosphorylation
themselves. The most critical part hereby lies in the so-called
activation loop. Upon phosphorylation of a certain residue
within the activation loop, the protein kinase active site is
reoriented to allow proper ATP and substrate binding. When
expressed in E. coli, PKA is catalytically active and undergoes
autophosphorylation. There are four phosphorylation sites
within PKA: S10, S139, T197 and S338. The recombinantly ex-
pressed protein is a mixture of diﬀerently phosphorylated iso-
forms with 2, 3 or 4 phosphate groups; the protein lacks a
unique phosphorylation pattern [10–12]. Phosphorylation of
T197 in the activation loop is essential for activity. Changing
T197 to alanine results in a folded, but unstable and inactive
protein. Phosphorylation of S338 has no inﬂuence on activity
but enhances protein stability [11,13]. For PKA, phosphoryla-
tion of residue S10 has not been found in preparations from
mammalian sources and a physiological role of S10 phosphor-
ylation has only recently been proposed [14]. Also, PKA from
mammalian tissues with phosphorylated S139 has not been ob-
served and there are currently no clues for any functional rel-
evance. The extent of phosphorylation of S10 and S139 in E.
coli is obviously dependent on the expression conditions.
To avoid the need for separating diﬀerently phosphory-
lated PKA isoforms we wondered whether it is possible to
produce active protein where the catalytic non-relevant
phosphorylation sites have been removed or even a ‘‘dephos-
pho’’-PKA lacking all phosphorylation sites. Since phos-
phorylation of S10 disorders the N-terminal helix [14] we
replaced S10 with alanine, whereas S139 and S338 were
changed to aspartate (PKA-3P). T197 was either replaced
by aspartate or glutamate resulting in PKA-4P(D) and
PKA-4P(E).
Since PKA serves as a Akt/PKB surrogate kinase in the
drug discovery process, two PKA constructs with 6 and 8. Published by Elsevier B.V. All rights reserved.
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Q84E/V104T/V123A/L173M/Q181K/F187L and additionally
S53T/L82K for PKAB8). Finally, the S10A, S139D and
S338D mutations were also introduced in the PKAB con-
structs yielding PKAB6-3P and PKAB8-3P, respectively.
The folding of all expressed proteins was checked by 2D
1H, 15N TROSY nuclear magnetic resonance spectroscopy
(NMR) and the activity of the proteins were assessed by
standard assays for enzymatic activity.2. Materials and methods
2.1. Cloning, expression and puriﬁcation of PKA
PKA was expressed in E. coli strain Bl21 (DE3)/pLysS (Novagen)
as described [13]. The DNA coding for PKA was originally cloned
from CHO cells (references cited in [13]). Site speciﬁc mutagenesis
was done following the Quick Change protocol (Stratagene). All
constructs have been veriﬁed by sequencing. To obtain uniformly
15N labeled protein, cells were grown in M9 minimal-medium
containing 15NH4Cl (Eurisotop, Saarbru¨cken, Germany) as the sole
nitrogen source. For all constructs, cell growth and protein expres-
sion was performed under the same conditions. Cells were grown
in the presence of appropriate antibiotics at 37 C until the OD600
reached 0.6 and then recombinant protein production was initiated
by adding 1 mM IPTG (isopropyl-b-D-thiogalactopyranoside).
Induction was carried out for 4 h at 28 C and cells were harvested
by centrifugation for 15 min at 4500g. PKA proteins were puriﬁed
with the aid of a His-tag as described in detail previously [13].
The His-tag was removed using a Tobacco Etch virus (Tev)-cleavage
site.
2.2. NMR spectroscopy
All protein samples were measured in the same buﬀer (150 mM
NaCl, 5 mM DTT, 50 mM HEPES, pH 6.5, 1 mM TSP, in 90%
H2O/10% D2O). Protein concentration was 0.25 mM for all prepara-
tions except for the ‘‘dephospho’’-forms PKA-4P(D) and PKA-
4P(E), where the protein was concentrated to 0.1 mM. 800 MHz 1D-
Watergate and 2D-TROSY [15] experiments (128 T1 increments) were
acquired at 298 K on a Bruker DRX800 spectrometer.
2.3. Enzymatic assay
Enzymatic activity of PKA proteins was checked with the aid of a
luminescent kinase assay following the manufacturers recommenda-
tions (Kinase-Glo, Promega, Madison, WI, USA). Kemptide (Prome-
ga) was used as substrate. The assay were performed in 96 well plates
with 50 mM HEPES, pH 7.5, 50 mM NaCl, 2 mM DTT, 10 mM
MgCl2, 2.5 lM ATP and 5 lM substrate peptide. The amount of em-
ployed PKA proteins was 74 nM in all assays. Samples were incubated
for 90 min at room temperature before addition of the Kinase-Glo
solution. After 20 min, luminescence was recorded with a Veritas
microplate luminometer (Turner BioSystems, Sunnyvale, CA, USA).
Data were analyzed using GraphPad Prism (GraphPad Software,
Inc., San Diego, CA, USA).Fig. 1. Structure of the PKA catalytic subunit. The structure is drawn
from pdb-ﬁle 1CTP with Swiss pdb-viewer. The side chains of the
amino acids that can be phosphorylated are shown as spheres. A
unique feature of PKA is the A-helix. The ATP-binding cleft lies
between the N- and C-terminal lobe.3. Results
All proteins were expressed under identical conditions at
28 C. For the ‘‘dephospho’’-PKA-4P(D) and PKA-4P(E)
proteins, most of the protein was expressed as insoluble inclu-
sion bodies. However, the yield of soluble protein was 1.5
and 1.0 mg/l M9 minimal medium for PKA-4P(D) and
PKA-4P(E), respectively. Typical expression yields for wild-
type PKA are 10 mg/l. For PKAB6 and PKAB8 similar
amounts of 10 mg/l were obtained. Interestingly, even higher
yields were obtained from the corresponding 3P forms (15–
20 mg/l). Except for the ‘‘dephospho’’-PKA-4P proteins, allPKA mutants could easily be concentrated up to 0.5 mM
without precipitation. Therefore, PKA-4P(D) and PKA-
4P(E) were only concentrated to 0.1 mM for NMR measure-
ments. The phosphorylation sites of PKA are depicted in
Fig. 1.
In order to evaluate whether the expressed proteins are cor-
rectly folded, 2D 1H, 15N TROSY NMR spectra were recorded
and compared with the corresponding spectrum of wild-type
PKA, for which NMR backbone assignment of PKA has re-
cently been published by us [13]. As shown in Fig. 2(a),
PKA-3P is properly folded. Some peaks are shifted, which is
obviously a result of the mutations. Concerning PKA-4P(D)
and PKA-4P(E) samples, there are certain amounts of un-
folded protein or only partially folded protein (Fig. 2(b) and
(c)).
Several PKAB chimeras have been characterized both func-
tionally and structurally [7,8]. We have extended this principle
by introducing further mutations leading to the new chimeras
PKAB6 and PKAB8 (Fig. 3). S53T and L82K are outside of
the ATP-binding pocket and may allow for designing small
molecule inhibitors that extend beyond the ATP-binding pock-
et and therefore confer more selectivity. Since PKA-3P can
easily be expressed and is stable, the corresponding mutations
were introduced in PKAB6 and PKAB8, resulting in PKAB6-
3P and PKAB8-3P, respectively. Again, correct folding of all
PKAB proteins was conﬁrmed by 2D 1H, 15N-NMR spectros-
copy. The diﬀerent PKA mutants display shifted peaks but the
overall peak pattern is similar compared to wild-type PKA
(Fig. 4).
Catalytic activity was monitored with a luminescent kinase
assay. The activity of wild-type PKA was set to 100%. The
results are shown in Fig. 5. PKA-3P is as active as wild-type
PKA and even the ‘‘dephospho’’-PKA-4P(D) and PKA-
4P(E) proteins display 57% and 39%, activity, respectively,
compared to wild-type PKA. PKAB6 and PKAB8 have re-
duced activity (15% and 10%, respectively). These results
were unexpected, but as a consequence of the introduced
Fig. 2. Comparison of TROSY spectra of wild-type PKA (black) with ‘‘dephospho’’-PKA mutants. (a) PKA-3P (green), (b) PKA-4P(D) (blue) and
(c) PKA-4P(E) (red). See text for details.
T. Langer et al. / FEBS Letters 579 (2005) 4049–4054 4051mutations, substrate binding might be compromised. Inter-
estingly, PKAB6-3P and PKAB8-3P were more active as
the corresponding phosphorylateable forms (28% and 43%
compared to wild-type PKA for PKAB6-3 and PKAB8-3,
respectively).4. Discussion
PKA containing S10A, S139D and S338Dmutations can eas-
ily be expressed in E. coli, the protein is folded and as active as
wild-type PKA. Replacing the additional phosphorylation site
Fig. 2 (continued)
Fig. 3. ATP binding site of PKA with bound ATP. The structure is
drawn from pdb-ﬁle 1ATP with Swiss pdb-viewer. The hinge region,
connecting the N- and C-terminal lobe of the protein, is indicated.
Mutations to enhance Akt/PKB similarity are displayed. Mutations
depicted in magenta belong to PKAB6 and the additional mutations
(indicated in blue) S53T and L82K pertain to PKAB8.
4052 T. Langer et al. / FEBS Letters 579 (2005) 4049–4054T197 by either D or E yields poorly soluble protein. Similar re-
sults have been described for the single mutants PKA T197D
and PKA T197E [11]. As reported previously PKA T197E
was found to be nearly inactive whereas PKA T197D has an
activity comparable to the wild-type [11]. By contrast, we have
measured signiﬁcant, albeit lower activity for both the PKA-
4P(D) and the PKA-4P(E) mutants (57% and 39% activity,
respectively) relative to the wild type. The physiological roleof S10 has been elucidated recently [14]. The N-terminus of
PKA folds into the so-called A-helix which is unique for
PKA. Mammalian PKA is myristoylated on Gly1, and Asn2
is deamidated. These modiﬁcations are absent if PKA is ex-
pressed in E. coli. Phosphorylation of S10 is presumed to alter
the structure and hence regulate the localization of PKA. It
does so by inducing destabilization and disorder of the ﬁrst nine
amino acids in S10-phosphorylated PKA, which otherwise
adopts an a-helical conformation in S10 unphosphorylated
PKA [14]. In an earlier report, Yonemoto et al. [11] describe
that PKA with only the S10Amutation yields poor soluble pro-
tein. However, the PKA-3P mutant with additional S139D and
S338D mutations is soluble, properly folded and can be ex-
pressed in high yields. Insertion of either aspartate or glutamate
instead of T197, which lies within the activation loop, resulted
in poorly soluble protein of lower quality. These observations
might be explained in that way, that S139D and S338D muta-
tions have a positive eﬀect on protein folding. This would be in
accordance with the protein stabilising eﬀect of S338 phosphor-
ylation. Replacing S338 by alanine yields a more unstable, but
fully active protein [13]. In contrast, changing S139 to alanine
does not display adverse eﬀects [11].
4.1. PKAB chimeras
PKA has been used as a surrogate kinase for Akt/PKB and
Rho [7–9]. To enhance the usefulness of PKA as Akt/PKB sur-
rogate, several mutations have been introduced within the
ATP binding site that correspond to Akt/PKB residues. Here,
we extend such PKAB chimeras with the introduction of S53T,
L82K and V104T mutations. S53 and L82 that are outside the
ATP-binding-pocket may be helpful in the design of inhibitors
Fig. 4. Comparison of TROSY spectra of wild-type PKA (black) with the PKAB chimerical proteins. (a) PKAB6 (magenta), PKAB6-3P(green) and
(b) PKAB8 (blue), PKAB8-3P (yellow).
T. Langer et al. / FEBS Letters 579 (2005) 4049–4054 4053that protrude from the ATP-binding pocket. PKAB6 and
PKAB8 can easily be expressed in E. coli and are properly
folded. Both mutants are less active than wild-type PKA. This
may be due to reduced aﬃnity for ATP or the substrate pep-
tide as a consequence of the introduced mutations. A 12-fold
reduced aﬃnity for ATP has been reported for the PKAQ84E/V123A/L173M/F187L mutant. The increase in yield
and activity for mutations at the phosphorylation sites
(S10A, S139D and S338D) is remarkable. This allows expres-
sion of PKA and PKAB chimeras with only the T197 phos-
phorylation site remained. Since no further phosphorylation
sites are present, no mixtures of diﬀerently phosphorylated
Fig. 5. Enzymatic activity of wild type PKA compared with ‘‘dephos-
pho’’-PKA, and PKAB chimerical proteins. Error bars represent the
standard error of the mean (SEM). The activity of wild-type PKA is set
as 100% and activity of PKA mutants are related to that. For
experimental details see Section 2.
4054 T. Langer et al. / FEBS Letters 579 (2005) 4049–4054isoforms occur and consequently there is no need for further
separation. This should be highly advantageous when the pro-
tein is used for X-ray crystallography and functional studies.
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